source
- Novartis reports Phase 3 pelacarsen trial fails to improve cardiovascular outcomesNovartis said its late-stage Phase 3 trial of the antisense drug pelacarsen did not show a benefit in reducing major cardiovascular events compared with placebo. The result adds to a recent string…
- Novo Nordisk halts two late-stage ziltivekimab heart trials after futility findingNovo Nordisk announced it has stopped work early on two additional late-stage clinical studies of its IL-6 inhibitor ziltivekimab, which was being evaluated for heart disease. The decision followe…